FDA approves Janssen’s AKEEGA to treat prostate cancer
14 Aug 2023
Clinical ResultPhase 3Drug Approval
Preview
Source: Pharmaceutical Technology
AKEEGA is intended for the treatment of metastatic castration-resistant prostate cancer. Credit: Chinnapong/Shutterstock.com.
The US Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s AKEEGA for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
A once-daily dual-action tablet, AKEEGA comprises a highly selective poly (ADP-ribose) polymerase inhibitorpoly (ADP-ribose) polymerase inhibitor, niraparib, and an androgen biosynthesis inhibitor, abiraterone acetate.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Docetaxel in Prostate Cancer GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Tivozanib Hydrochloride in Prostate Cancer GlobalData
View allCompanies IntelligenceJanssen IncView all
It is indicated with prednisone to treat adults with mCRPC and BRCA[a specific cancer gene]-positive mutations.
AKEEGA is available in 200mg and 100mg niraparib/1,000mg abiraterone acetate dosages. The high dosage is the recommended starting dose while the low dosage is available for dose reduction.
The approval is based on positive results from the Phase III MAGNITUDE study that evaluated the combination therapy.
In the multi-centre, placebo-controlled, double-blind, randomised study, a statistically significant risk reduction of 47% was observed for radiographic progression-free survival (rPFS) in BRCA-positive patients.
The safety profile of the combined therapy was consistent with the known profile of each monotherapy approved by the FDA, with serious adverse events (AEs) reported in 41% of patients.
More than 20% of patients experienced the most common AEs: nausea, constipation, fatigue, hypertension and musculoskeletal pain. 15% permanently discontinued due to an adverse reaction.
Janssen research and development (solid tumours) clinical development vice-president Kiran Patel stated: “Janssen’s legacy of advancing the science of prostate cancer has contributed to the evolution of transformational treatment approaches for more than a decade.
“This milestone, which marks the approval of Janssen’s third prostate cancer treatment, highlights the importance of advancing precision medicine approaches and genetic testing for the treatment of patients with BRCA-positive mCRPC.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.